Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $413.53M
• Dividend Yield: N/A
• Average Volume (3M): 213.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: -71.42%
• EPS Growth: -248.91%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.06
• Shares Outstanding: 38,219,230
• 10 Day Avg. Volume: 269,934
• 30 Day Avg. Volume: 213,025
• PEG Ratio: -0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 3.06
• P/FCF Ratio: -14.43
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 5.59
• Enterprise Value/Gross Profit: 14.85
• Enterprise Value/Ebitda: -3.02
• 1Y Price Target: $18.00
• Price Target Upside: 66.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -4.13
• Revenue Forecast (FY): $20.18M

• Rating: 52 Neutral
• Price Target: $12.00 ▲(10.91% Upside)

The score is held back primarily by weak financial performance (declining revenue, ongoing losses, and negative cash flows). Offsetting factors include favorable technical trends (price above key moving averages with positive MACD) and a positive corporate update highlighting meaningful pipeline and regulatory progress with runway into Q3 2027; valuation remains challenged due to loss-making status and no dividend data.

Positive Factors

Platform & Delivery Technology

Entrada's proprietary intracellular delivery platform targets transport of proteins and nucleic acids into cells, a structural competitive advantage. A platform approach supports multiple programs across neuromuscular and ocular indications, enabling reuse of core technology and improving long-term R&D efficiency and partner appeal.

Conservative Leverage

A 0.15 debt/equity ratio provides durable balance-sheet flexibility: lower interest burden and reduced default risk. For a pre-revenue biotech, conservative leverage preserves optionality to fund clinical programs via partnerships or equity without high fixed financial commitments, supporting multi-stage development timelines.

Pipeline & Regulatory Momentum

Progress across multiple RNA-based programs, regulatory RPD designation, and program initiations materially de-risks near-term development milestones. Selection of an ocular candidate expands addressable indications. Combined with a stated cash runway into Q3 2027, these are lasting structural positives for milestone-driven value creation and partnership potential.

Negative Factors

Declining Revenue

A persistent revenue decline indicates the company’s funding from collaborations or milestones is not steadily growing. Over 2–6 months this reduces internal funding capacity for R&D, increases reliance on new deals or financing, and weakens the firm's ability to self-fund clinical advancement without dilution or concessions to partners.

Negative Cash Flow

Sustained negative operating and free cash flows show ongoing burn from clinical R&D. Even with stated runway, negative cash flow is a structural risk: absent new milestone receipts or financing, the firm will need external capital, which can dilute shareholders and constrain timing or scope of development programs.

Ongoing Losses & Negative Profitability

Continued negative profitability and negative ROE reflect that operations do not yet generate returns. This limits reinvestment capacity, heightens dependence on external funding, and reduces strategic flexibility to commercialize or scale programs. Structural unprofitability raises execution and financing risk over the medium term.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Weak fundamentals: revenue decline (-22.59% TTM), negative profitability (net profit/EBIT margins), and negative operating/free cash flow. A low debt-to-equity ratio (0.15) supports balance-sheet stability but does not offset persistent losses.

Income Statement

Entrada Therapeutics Inc has experienced a significant decline in revenue with a negative growth rate of -22.59% in the TTM period. The company is facing challenges with profitability, as evidenced by negative net profit and EBIT margins. Despite a high gross profit margin, the overall financial performance is hindered by substantial operating losses.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.15, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is stable, suggesting a solid capital structure despite profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and accounting profits, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.52M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	23.16M	210.78M	129.01M	0.00	0.00	-326.00K
EBITDA	-113.78M	47.01M	-321.00K	-95.35M	-50.01M	-26.20M
Net Income	-103.45M	65.63M	-6.68M	-94.62M	-51.16M	-26.52M
Balance Sheet
Total Assets	412.90M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	326.84M	420.00M	351.97M	188.71M	291.06M	39.05M
Total Debt	52.40M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	72.18M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	340.72M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-129.80M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-127.91M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	141.05M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	2.10M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.82
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Neutral. The current price of 10.82 is below the 20-day moving average (MA) of 10.96, above the 50-day MA of 10.68, and above the 200-day MA of 7.80, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 41.57 is Neutral, neither overbought nor oversold. The STOCH value of 36.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$136.17M	5.95	19.23%	―	―	―
VTYX	57 Neutral	$998.04M	-9.30	-45.35%	―	―	36.65%
TRDA	52 Neutral	$413.53M	―	-27.11%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMT	49 Neutral	$188.49M	-3.04	-39.78%	―	―	-38.23%
CCCC	47 Neutral	$183.17M	-1.02	-59.98%	―	-10.57%	1.98%

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics highlights RNA pipeline progress and outlook

On January 8, 2026, Entrada Therapeutics reported significant 2025–early 2026 progress across its RNA-based pipeline for neuromuscular and ocular diseases, including completion of Cohort 1 dosing in the global Phase 1/2 MAD ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy (DMD), transition to the open-label Phase 2 portion, and receipt of Rare Pediatric Disease Designation from the U.S. FDA in December 2025. The company has initiated dosing in the Phase 1/2 MAD ELEVATE-45-201 trial of ENTR-601-45, secured U.K. authorization to start a Phase 1/2 MAD study of ENTR-601-50 in DMD patients amenable to exon 50 skipping, plans regulatory filings for ENTR-601-51 in 2026, and continues to support Vertex’s ongoing global Phase 1/2 trial of VX-670 in myotonic dystrophy type 1, targeting completion of the MAD portion’s enrollment and dosing in the first half of 2026. Entrada also expanded into ophthalmology by selecting ENTR-801 in December 2025 as its first ocular clinical candidate for Usher syndrome type 2A, supported by robust preclinical data, and indicated that around 15,000 US and European patients may be addressable by exon 13 skipping; coupled with a reported cash runway into the third quarter of 2027 and a high-profile investor presentation scheduled for January 14, 2026 at the J.P. Morgan Healthcare Conference, these developments underscore the company’s intent to solidify its position as a leading player in RNA-based therapies for high-unmet-need genetic diseases.

The most recent analyst rating on (TRDA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.